tbResList Print — GB gefitinib, erlotinib

Filters: qv=7, qv2=%, rfv=%

Product

GB gefitinib, erlotinib
Description: <b>selectively</b> targeting the mutant proteins in malignant cells. <br>
epidermal growth factor receptor (EGFR) inhibitors (lung cancer)<br>

Pathway results for Effect on Cancer / Diseased Cells

Mitochondria & Bioenergetics(tgid=3) ⓘ

MEK↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

PDK1↓, 1,   S6K↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   Apoptosis↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Sp1/3/4↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

miR-205↑, 1,   miR-218↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↓, 1,   Let-7↑, 1,  

Migration(tgid=13) ⓘ

miR-200b↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

EGFR↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 2,  
Total Targets: 14

Pathway results for Effect on Normal Cells

Total Targets: 0

Research papers

Year Title Authors PMID Link Flag
2019Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell deathPing Chen—https://pmc.ncbi.nlm.nih.gov/articles/PMC6567416/0
2017Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cellsZheng Yang28870456https://pubmed.ncbi.nlm.nih.gov/28870456/0
2019Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAsMohd FarhanPMC6413107https://pmc.ncbi.nlm.nih.gov/articles/PMC6413107/0